Antibody programs in early discovery move through three distinct production stages, each with a different scientific purpose, volume requirement, and decision milestone. Treating these stages as interchangeable, or jumping from screening directly to large-scale manufacturing, is one of the most common ways to accumulate avoidable costs and unresolved scientific risk.
This article focuses on the two stages that define the preclinical journey: High-Throughput (HTP) Antibody Production for lead selection, and Intermediate-Scale Production for lead characterization and early in vivo work. Looking for an HTP or preclinical-scale production partner?
Three Stages of Antibody Production: One Pipeline
Recombinant antibody expression in early drug discovery follows a three-stage logic. Understanding where each stage begins and ends is the foundation of any sound production strategy.
Investing in preclinical scale-up requires complete confidence in your initial screening data. If your selection is based on uncorrected datasets, hidden batch effects in HTP antibody production may lead you to scale up false-positive candidates that fail under bioreactor conditions.
Before committing resources to larger volumes, teams must maximize their early-stage data. Leveraging all of the Benefits of High-Throughput Antibody Expression ensures that only the most developable candidates are selected for preclinical scale-up.
| Stage 1: HTP | Stage 2: Preclinical Scale | Stage 3: Clinical / GMP | |
|---|---|---|---|
| Primary Goal | Lead selection from large candidate panels | Candidate characterization, lead confirmation, early in vivo | Clinical supply under GMP conditions |
| Typical Throughput | 24 to several hundred variants | Typically 3 to 20 candidates | 1 lead |
| Typical Yield | 100 μg to 1.5 mg per variant | 1 mg to 1 g per candidate | Grams to kilograms |
| Expression | Transient CHO | Transient CHO | Stable CHO cell lines (GMP) |
| Key Question | Which candidates advance? | Is this lead viable preclinically? | Is this molecule ready for humans? |
| evitria Scope | ✓ Covered | ✓ Covered | Possible through evitria partner |
evitria supports the first two stages. Stage 3, large-scale GMP manufacturing for clinical development, requires a different regulatory infrastructure and lies outside our scope. Our specialized partner ProBioGen can support GMP manufacturing and continue your development pipeline in a seamless manner.
Before initiating Stage 1, HTP screening campaign design — including panel size, batching strategy, and comparability controls — determines whether the output will support confident stage progression.
Stage 1: HTP Production for Lead Selection
High-throughput production is optimized for breadth. The goal is to move from a large pool of candidate sequences to a shortlist of leads worth investigating further. Parallel expression of 24 to several hundred variants generates material in the range of 100 μg to 1.5 mg per construct, which is sufficient to confirm expression and support early comparative binding or developability assessments.
Candidate sequences may originate from hybridoma campaigns, single B-cell technologies, phage display, synthetic libraries, or AI-driven design. Regardless of origin, data comparability across the panel is the critical parameter. If the production process introduces variability between constructs, the resulting data reflects the process rather than the biology.
Automation and standardized CHO-based workflows are therefore prerequisites for data that can be trusted.
Stage 2: Preclinical-Scale Production for Lead Characterization
Once a shortlist has been established through HTP, the program enters a fundamentally different phase. Preclinical-scale production is optimized for depth. The question is no longer which candidates look promising, but whether the most promising candidate is robust enough to justify the investments that follow.
Material requirements at this stage fall in the range of 1 mg to 1 g. This volume supports comprehensive biophysical profiling, including aggregation analysis, thermal stability, and binding kinetics,[1] as well as functional cell-based assays.
It also enables early in vivo feasibility studies in rodent models, which represent the first direct evidence of a molecule’s behavior in a living system. Pharmacodynamics and pharmacokinetics parameters are identified at this stage as well as first in vivo efficacy.
This is also the stage where developability liabilities surface and where lead candidates can be refined before any commitment to large-scale manufacturing. A molecule that advances to clinical-stage production without passing through this intermediate step carries unresolved scientific risk that becomes exponentially more expensive to address later.
Stage 3: Large-Scale GMP Production for Clinical Development
The third stage, large-scale manufacturing under GMP conditions, lies beyond the preclinical horizon. It is reserved for molecules that have been fully de-risked through the first two stages and are ready to enter human clinical trials. Production volumes in this phase range from grams to kilograms, manufactured in bioreactors of several hundred to over 2,000 liters.
This stage demands stable cell line development, extensive process characterization, regulatory documentation, and a quality management infrastructure that is categorically different from the flexibility-first environment of early discovery. The transition to this stage is a major strategic and financial commitment that should only be made once preclinical data has clearly justified it.
The decision criteria for this transition, including sequence lock, volume requirements, and regulatory compliance, are examined in detail in Transient vs. Stable Expression in High-Throughput Antibody Screening: When to Switch.
evitria operates at the first two stages of this progression. The work done there, the lead selection and the preclinical characterization, is precisely where the quality of early-stage decisions determines whether a molecule has a viable path forward.
Why CHO Consistency Across Both HTP and Preclinical Stages Matters
HEK293 cells are frequently used for early HTP screening because of their speed and accessibility. However, HEK293 and CHO cells differ in glycosylation profiles and folding efficiencies. An antibody that performs well in a HEK293-based screen may behave differently when re-expressed in CHO at preclinical scale.[2]
When this divergence occurs, the program must either invest in re-screening new molecules or optimize and engineer the lead molecule further. Using CHO as the production system from the very first HTP transfection eliminates this variable.
Data generated at the HTP stage and data generated at preclinical scale reflect the same biological environment, and performance differences can be attributed to the molecule rather than the process. The specific host-system and production artefacts responsible for this failure mode are detailed in why HTP screening results sometimes fail to translate to manufacturing:
This is also consequential for AI-driven discovery workflows. Machine learning models trained on HTP expression data require the host system to be a constant.
Working with evitria Across HTP and Preclinical-Scale Stages
evitria conducts all production within the same proprietary CHO transient platform, from small-scale HTP antibody production service campaigns to gram-level preclinical supply. Because the same expression system is used at both stages, candidates advance without host-switch corrections or re-optimization delays.
Every project initiates within 24 hours at our Zurich facility. The standard QC package at both stages includes concentration and titer measurement, HPLC-SEC, CE-SDS, and endotoxin analysis. For preclinical-scale programs, extended characterization is available through our curated partner network, covering downstream biophysical profiling, functional assays, and in vivo services.
Every production strategy is individually designed in dialogue with the scientist. We can adapt to the molecule, the decision stage, and the specific requirements of the program.
Discuss your screening and preclinical production strategy with our team.
Frequently Asked Questions About HTP and Preclinical-Scale Antibody Production
HTP is designed for breadth, enabling parallel expression of a large number of variants at small volumes to identify leads. Preclinical-scale production is designed for depth, providing higher volumes of a small number of candidates for comprehensive characterization and early in vivo work. The two stages answer different scientific questions and serve different purposes in the pipeline.
HTP material is no longer sufficient when the program requires quantitative biophysical profiling, comparative functional assays, or material for in vivo studies. These applications require volumes beyond what high-throughput formats are designed to provide.
HEK293 and CHO cells differ in glycosylation and folding behavior. A candidate screened in HEK293 may perform differently when re-expressed in CHO for preclinical characterization. This host-switch effect introduces ambiguity that is difficult to resolve without re-screening. Using CHO from the first transfection eliminates this source of uncertainty.
No. evitria supports the research and preclinical stages only. Large-scale GMP manufacturing for clinical development requires a different regulatory infrastructure that lies outside our scope. Our role is to ensure that candidates arriving at that stage are well-characterized and de-risked, and we have expert partners in our network who can take over the GMP work seamlessly.
Sources
- Jain, T., Sun, T., Durand, S., Hall, A., Houston, N. R., Nett, J. H., Sharkey, B., Bobrowicz, B., Caffry, I., Yu, Y., Cao, Y., Lynaugh, H., Brown, M., Baruah, H., Gray, L. T., Krauland, E. M., Xu, Y., Vásquez, M., & Wittrup, K. D. (2017). Biophysical properties of the clinical-stage antibody landscape. Proceedings of the National Academy of Sciences, 114(5), 944–949. https://doi.org/10.1073/pnas.1616408114
- Liang, K., Luo, H., & Li, Q. (2023). Enhancing and stabilizing monoclonal antibody production by Chinese hamster ovary (CHO) cells with optimized perfusion culture strategies. Frontiers in Bioengineering and Biotechnology, 11, 1112349. https://doi.org/10.3389/fbioe.2023.1112349